More recently, a bispecific EpCAM/CD3-antibody, antibody–drug conjugates (ADCs), and an antibody–cytokine fusion protein (termed immunocytokine) have emerged as promising EpCAM-targeting approaches for cancer treatment [9]. This evidence concerns the gene EPCAM and cancer.